Palabras clave
cirugía de la válvula mitral
insuficiencia mitral funcional
ensayo controlado aleatorizado
insuficiencia mitral secundaria
reparación transcatéter de borde a borde
Cómo citar
Resumen
El estudio MATTERHORN es el único ensayo controlado aleatorizado hasta la fecha que compara la cirugía de la válvula mitral con la reparación transcatéter de borde a borde para la insuficiencia mitral funcional en pacientes sintomáticos no aptos para cirugía de revascularización coronaria. Este estudio presenta limitaciones significativas. La exclusión de la cirugía de revascularización coronaria es una omisión crítica, ya que es la intervención principal para mejorar la supervivencia en estos pacientes, mientras que la cirugía aislada de la válvula mitral aborda principalmente los síntomas y la calidad de vida. Además, numerosas deficiencias metodológicas y defectos inherentes comprometen la validez interna del ensayo y su aplicabilidad más amplia en la práctica clínica. Por lo tanto, es esencial realizar una reevaluación exhaustiva que destaque estos sesgos, deficiencias metodológicas y limitaciones,
sobre todo ante la posible aparición de guías clínicas nuevas.
Citas
Baldus S, Doenst T, Pfister R, et al; MATTERHORN Investigators. Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation. N Engl J Med. 2024;391(19):1787-1798. https://doi.org/10.1056/NEJMoa2408739.
ClinicalTrials.gov [Internet]. A Multicenter, Randomized, Controlled Study to Assess Mitral Valve Reconstruction for Advanced Insufficiency of Functional or Ischemic Origin (MATTERHORN). ClinicalTrials.gov; [consultado el 3 de junio de 2025]. Disponible en: https://clinicaltrials.gov/study/NCT02371512
Leung JT, Barnes SL, Lo ST, Leung DY. Non-inferiority trials in cardiology: what clinicians need to know. Heart. 2020;106(2):99-104. https://doi.org/10.1136/heartjnl-2019-315772.
Newell P, Tartarini R, Hirji S, et al. Observed versus expected morbidity and mortality in patients undergoing mitral valve repair. Interact Cardiovasc Thorac Surg. 2022;35(5):ivac241. https://doi.org/10.1093/icvts/ivac241.
Chen QF, Zhou X, Katsouras CS, et al. Atrial and ventricular functional mitral regurgitation: prevalence, characteristics, outcomes, and disease progression. Eur Heart J Cardiovasc Imaging. 2025;26(3):545-556. https://doi.org/10.1093/ehjci/jeae309.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients Witwithlvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e35-e71. https://doi.org/10.1161/CIR.0000000000000932.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. https://doi.org/10.1093/eurheartj/ehab395.
García-Villareal OA. Is there still a role for isolated mitral valve surgery in functional mitral regurgitation? A contemporary review. Gac Med Mex 2025; 161:1-9. https://doi.org/10.24875/GMM.25000018.
Chikwe J, Kittleson MM. Transcatheter Repair or Surgery for Functional Mitral Regurgitation. N Engl J Med. 2024 Nov 14;391(19):1850-1851. https://doi.org/10.1056/NEJMe2411217.
García-Villarreal OA, Rodríguez-Durán LE. A study that fails to move the needle: MATTERHORN and the confirmation of the obvious in a highly selective population. Cir Card Mex. 2025;10(2):31-34. https://doi.org/10.35366/119667.
Acker MA, Parides MK, Perrault LP, et al; CTSN. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2014;370(1):23-32. https://doi.org/10.1056/NEJMoa1312808.
Goldstein D, Moskowitz AJ, Gelijns AC, et al; CTSN. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med. 2016;374(4):344-53. https://doi.org/10.1056/NEJMoa1512913.
Lancellotti P, Tribouilloy C, Hagendorff A, et al; Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14(7):611-644. https://doi.org/10.1093/ehjci/jet105.
Daimon M, Fukuda S, Adams DH, et al. Mitral valve repair with Carpentier-McCarthy-Adams IMR ETlogix annuloplasty ring for ischemic mitral regurgitation: early echocardiographic results from a multicenter study. Circulation. 2006;114(1 Suppl):I588-593. https://doi.org/10.1161/CIRCULATIONAHA.105.001347.
Mosquera VX, Bouzas-Mosquera A, Estévez F, et al. Mitral valve repair for ischemic mitral regurgitation using the Carpentier-McCarthy Adams IMR ETlogix® ring: medium-term echocardiographic findings. Rev Esp Cardiol. 2010;63(10):1200-4. English, Spanish. https://doi.org/10.1016/s1885-5857(10)70235-8.
Gatti G, Pinamonti B, Dell'Angela L, et al. Mitral annuloplasty with IMR ETlogix ring for ischemic mitral regurgitation and left ventricular dysfunction. J Heart Valve Dis. 2012 Sep;21(5):556-563.
Timek TA, Malinowski M, Hooker RL, et al. Long-term outcomes of etiology specific annuloplasty ring repair of ischemic mitral regurgitation. Ann Cardiothorac Surg. 2021;10(1):141-148. https://doi.org/10.21037/acs-2020-mv-fs-0166.
Mitral Valve Repair Center [Internet]. Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring; [consultado el 3 de junio de 2025]. Disponible en: https://www.mitralvalverepair.org/carpentier-mccarthyadams-imr-etlogix-annuloplasty-ring
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303-371. https://doi.org/10.1016/j.echo.2017.01.007.
Wang H, Gammie JS. A Slippery Slope: Extrapolating MATTERHORN's Findings to Clinical Practice. Ann Thorac Surg. 2025:S0003-4975(25)00405-9. https://doi.org/10.1016/j.athoracsur.2025.04.023.
Heidenreich PA, Bozkurt B, Aguilar D, et al; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. https://doi.org/10.1161/CIR.0000000000001063.
Fonarow GC, Greene SJ. Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: Strong Impact Across Ejection Fraction Spectrum. J Am Coll Cardiol. 2023;81(22):2145-2148. https://doi.org/10.1016/j.jacc.2023.04.006.
Heart Failure Society of America. FDA approves new treatment for a type of heart failure [Internet]. 2020, may 5 [consultado el 3 de junio de 2025]. Disponible en: https://wayback.archive-it.org/7993/20201226154106/https://www.fda.gov/news-vents/pressannouncements/fda-approves-new-treatment-type-heart-failure.
Adamo M, Tomasoni D, Stolz L. Impact of Transcatheter Edgeto-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration. JACC Cardiovasc Interv. 2023;16(8):896-905. https://doi.org/10.1016/j.jcin.2023.01.362.
García-Villarreal OA. Elevated mitral valve gradient after transcatheter edge-to-edge repair: a risk falling through the cracks. Narrative review. Gac Med Mex 2024 [Internet]. 27 de diciembre de 2024 [consultado el 3 de junio de 2025];160(6): 585-591. https://doi.org/10.24875/gmm.m24000908.
García-Villarreal OA. Reoperation Rate Versus Failure Rate as Quality Indicators in Transcatheter Edge-to-Edge Repair for Mitral Regurgitation. Am J Cardiol. 2024;231:70-71. https://doi.org/10.1016/j.amjcard.2024.08.036.